NATIENS: Optimal Management and Mechanisms of SJS/TEN
NATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis NATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Man ...
Etanercept therapy for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) cases of refractory to systemic steroid therapy Etanercepttherapy for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) cases of r ...
open-label, multicenter, single-arm study to evaluate the efficacy and safety of etanercept in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis who were ineffective with systemic steroid therapy open-label, multicenter, single-arm study to evaluate the efficacy and safety of etanerceptin patien ...
Etanercept 50 mg / day is subcutaneously administered on the first day (Day 1). If epithelialization is not complete, administer once on day 8 (Day 8) and day 15 (Day 15) as needed. Etanercept50 mg / day is subcutaneously administered on the first day (Day 1). If epithelialization ...